Pfizer Inc. (PFE) Shares Bought by Murphy Capital Management Inc.
Murphy Capital Management Inc. raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 67,464 shares of the biopharmaceutical company’s stock after buying an additional 3,017 shares during the period. Murphy Capital Management Inc.’s holdings in Pfizer were worth $2,375,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also bought and sold shares of the company. State of Alaska Department of Revenue raised its position in Pfizer by 11.3% in the second quarter. State of Alaska Department of Revenue now owns 371,887 shares of the biopharmaceutical company’s stock valued at $13,093,000 after buying an additional 37,647 shares during the period. Nordea Investment Management AB raised its position in Pfizer by 4.8% in the second quarter. Nordea Investment Management AB now owns 27,591,965 shares of the biopharmaceutical company’s stock valued at $971,513,000 after buying an additional 1,273,953 shares during the period. Private Trust Co. NA raised its position in Pfizer by 1.4% in the second quarter. Private Trust Co. NA now owns 116,539 shares of the biopharmaceutical company’s stock valued at $4,103,000 after buying an additional 1,583 shares during the period. Moon Capital Management LLC acquired a new position in Pfizer during the second quarter valued at approximately $237,000. Finally, Telemus Capital LLC raised its position in Pfizer by 31.2% in the second quarter. Telemus Capital LLC now owns 24,951 shares of the biopharmaceutical company’s stock valued at $879,000 after buying an additional 5,930 shares during the period. 69.66% of the stock is owned by institutional investors and hedge funds.
Pfizer Inc. (NYSE:PFE) traded up 0.15% during mid-day trading on Monday, reaching $33.61. 16,383,660 shares of the company’s stock traded hands. Pfizer Inc. has a 1-year low of $28.25 and a 1-year high of $37.39. The firm has a 50-day moving average price of $34.25 and a 200-day moving average price of $34.28. The stock has a market cap of $203.87 billion, a P/E ratio of 29.80 and a beta of 0.86.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.02. The business had revenue of $13.10 billion for the quarter, compared to the consensus estimate of $13.01 billion. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. Pfizer’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same period last year, the company posted $0.56 EPS. Equities research analysts anticipate that Pfizer Inc. will post $2.46 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be given a $0.30 dividend. The ex-dividend date is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.57%. Pfizer’s dividend payout ratio is 95.24%.
Several analysts recently weighed in on PFE shares. Jefferies Group cut their price objective on shares of Pfizer from $42.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, June 20th. Deutsche Bank AG reiterated a “buy” rating on shares of Pfizer in a research report on Wednesday, June 15th. Vetr downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating and set a $37.28 price objective on the stock. in a research report on Tuesday, June 28th. Piper Jaffray Cos. set a $54.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, July 25th. Finally, JPMorgan Chase & Co. set a $40.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, July 25th. Ten investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. Pfizer has a consensus rating of “Buy” and a consensus price target of $38.78.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.